scholarly journals Subpleural curvilinear shadow of eosinophilic pneumonia simulating pneumothorax

2021 ◽  
Vol 69 (4) ◽  
pp. 569-571
Author(s):  
So Hattori ◽  
Yuika Sasatani ◽  
Hiroaki Satoh
1995 ◽  
Vol 32 (5) ◽  
pp. 733
Author(s):  
Hae Jeong Jeon ◽  
Jeong Hee Park ◽  
Jong Nam Lim ◽  
Tae Haeng Heo ◽  
Hyun Jun Shin

2019 ◽  
Vol 40 (1) ◽  
pp. 42-46 ◽  
Author(s):  
Y Charaf ◽  
JP Potier ◽  
T Njambou ◽  
L Hubin ◽  
V Vandermoten ◽  
...  

2021 ◽  
Vol 156 (3) ◽  
pp. 148-149
Author(s):  
Raquel Fernández-González ◽  
María Dolores Díaz López ◽  
Ana María Lorenzo Vizcaya ◽  
Amara González Noya

Antibiotics ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 446
Author(s):  
Laura Soldevila-Boixader ◽  
Bernat Villanueva ◽  
Marta Ulldemolins ◽  
Eva Benavent ◽  
Ariadna Padulles ◽  
...  

Background: Daptomycin-induced eosinophilic pneumonia (DEP) is a rare but severe adverse effect and the risk factors are unknown. The aim of this study was to determine risk factors for DEP. Methods: A retrospective cohort study was performed at the Bone and Joint Infection Unit of the Hospital Universitari Bellvitge (January 2014–December 2018). To identify risk factors for DEP, cases were divided into two groups: those who developed DEP and those without DEP. Results: Among the whole cohort (n = 229) we identified 11 DEP cases (4.8%) and this percentage almost doubled in the subgroup of patients ≥70 years (8.1%). The risk factors for DEP were age ≥70 years (HR 10.19, 95%CI 1.28–80.93), therapy >14 days (7.71, 1.98–30.09) and total cumulative dose of daptomycin ≥10 g (5.30, 1.14–24.66). Conclusions: Clinicians should monitor cumulative daptomycin dosage to minimize DEP risk, and be cautious particularly in older patients when the total dose of daptomycin exceeds 10 g.


Respiration ◽  
2003 ◽  
Vol 70 (4) ◽  
pp. 362-366 ◽  
Author(s):  
Masayoshi Minakuchi ◽  
Akio Niimi ◽  
Hisako Matsumoto ◽  
Ryoichi Amitani ◽  
Michiaki Mishima

Sign in / Sign up

Export Citation Format

Share Document